Will GNPX stock go up?

**The outlook for Genprex (GNPX) stock is uncertain**, and several factors contribute to this assessment:

1. **Current Stock Performance and Market Sentiment**:
- **Recent Price and Percentage Change**: The closing price of GNPX on October 18, 2024, was $0.41. The stock experienced a 21.9% increase over the past week but a 5.9% increase over the past month.
- **Short-term Trend Forecast**: The short-term trend forecast for GNPX is bearish.
- **Moving Averages**: The 5-day moving average is $0.36, and the 10-day moving average is $0.35. Both moving averages are below the current closing price, indicating a potential for the stock to trend downwards if market sentiment does not improve.

2. **Company's Strategic Developments**:
- **Nasdaq Delisting Warning**: Genprex has been notified that it is at risk of being delisted from Nasdaq due to non-compliance with the minimum bid price requirement. This is a significant risk that could lead to further stock price volatility and potential investor uncertainty.
- **Clinical Trial Progress**: Despite the stock price struggles, the company has made progress in its clinical trials, with positive outcomes in lung cancer gene therapy trials. This could potentially lead to improved investor confidence if the results in humans are as positive as the preclinical data suggest.
- **Spin-off Plans**: Genprex plans to spin off its diabetes gene therapy program into a new subsidiary, which could be seen as a strategic move to focus on core competencies and improve the company's financial health.
3. **Market Position and Future Prospects**:
- **Biotech Industry Volatility**: The biotech industry is inherently volatile, with significant price fluctuations common due to the high risk and uncertainty associated with drug development.
- **Innovation and Partnerships**: The company's emphasis on innovation, as evidenced by the formation of a Mesothelioma Clinical Advisory Board and plans to spin off the diabetes program, suggests a forward-looking approach. These developments could potentially attract investors looking for growth opportunities.

In conclusion, while there are positive developments in the company's research and strategic planning, the current stock price and the risk of Nasdaq delisting create a complex situation. The decision to buy or hold GNPX stock should be based on an individual's risk tolerance, investment horizon, and confidence in the company's ability to regain compliance with Nasdaq listing requirements and execute its strategic plans.